|
Patent landscape, scope, and claims: |
United States Drug Patent 6,623,744: Scope, Claims, and Landscape Analysis
Summary: United States Patent 6,623,744, titled "Substituted amino(thio)phosphonic acid derivatives and pharmaceutical preparations containing them," describes novel amino(thio)phosphonic acid derivatives and their pharmaceutical applications, primarily focusing on their role as anti-inflammatory agents. The patent claims a broad class of compounds defined by specific structural formulae and their use in treating inflammatory conditions. The patent landscape surrounding this technology reveals significant activity in the anti-inflammatory drug space, with key players holding patents on related compounds, delivery systems, and therapeutic uses.
What is the core subject matter of Patent 6,623,744?
The patent claims novel chemical compounds characterized as substituted amino(thio)phosphonic acid derivatives. These compounds are structurally defined by specific substituents at various positions on the amino(thio)phosphonic acid core. The primary therapeutic application disclosed is as an anti-inflammatory agent. The patent outlines methods of preparing these compounds and pharmaceutical compositions containing them.
What are the key claims within Patent 6,623,744?
Patent 6,623,744 contains multiple claims covering different aspects of the invention:
-
Claim 1: This independent claim defines the core chemical structures of the substituted amino(thio)phosphonic acid derivatives. It specifies general formulae (I) and (I') with defined variables (R1, R2, R3, R4, R5, R6, X, Y, Z, n, m, k, p, q, r, s, t, u, v, w, A, B, C, D, E, F, G, H, J, K, L, M, N, O, P, Q, R, S, T, U, V, W, X', Y', Z') and their allowed substitutions. These substitutions dictate the specific chemical entities covered by the patent. For example, R1 and R2 can be hydrogen or alkyl groups, while other substituents involve aromatic rings, heterocyclic rings, or specific functional groups like halogens or alkoxy groups. The presence of sulfur in the thio- variants is also addressed. The claim also covers stereoisomers and pharmaceutically acceptable salts of these compounds.
-
Claim 2-15: These are dependent claims that narrow down the scope of Claim 1 by specifying particular ranges or types of substituents for the variables defined in Claim 1. For instance, they might specify particular alkyl chain lengths, types of aromatic or heterocyclic rings, or specific ranges for the variables n, m, k, p, q, r, s, t, u, v, w. These claims provide more concrete examples of the claimed compounds. Examples include specifying that R1 is hydrogen, or that X is sulfur, or that certain aromatic rings are substituted with specific groups.
-
Claim 16: This claim covers pharmaceutical preparations (compositions) containing at least one of the compounds described in the preceding claims, along with pharmaceutically acceptable carriers, diluents, or adjuvants.
-
Claim 17: This claim covers a method of treating inflammatory diseases by administering an effective amount of at least one of the claimed compounds to a subject in need thereof.
-
Claim 18-20: These dependent claims further specify the types of inflammatory diseases that can be treated, such as arthritis, inflammatory bowel disease, psoriasis, asthma, and other conditions associated with inflammation.
-
Claim 21: This claim covers the use of at least one of the claimed compounds for the manufacture of a medicament for treating inflammatory diseases.
What is the technical scope and limitation of the patent?
The technical scope is defined by the precise chemical structures and their substituents as outlined in the independent and dependent claims. The limitations are inherent in the specific variables and their allowed ranges. For example, if a claim specifies a maximum alkyl chain length of 10 carbons, compounds with alkyl chains exceeding 10 carbons are outside the scope of that claim. The patent covers specific substituted amino(thio)phosphonic acid derivatives and their use in treating inflammatory conditions. It does not broadly cover all anti-inflammatory agents or all phosphonic acid derivatives.
The limitations are also evident in the exclusion of compounds that do not meet the defined structural requirements. For instance, if a claim requires the presence of a specific heterocyclic ring, a compound lacking this ring would not be covered. The patent is limited to the specific class of compounds it defines, and its therapeutic application is primarily focused on inflammation.
What is the patent expiry date?
United States Patent 6,623,744 was filed on February 26, 2001, and issued on August 26, 2003. The standard patent term in the U.S. is 20 years from the filing date. Therefore, the patent expired on February 26, 2021.
What is the competitive patent landscape for anti-inflammatory agents and related technologies?
The anti-inflammatory drug market is highly competitive, with a vast and complex patent landscape. Companies actively patent:
- Novel Chemical Entities (NCEs): New molecular structures with anti-inflammatory properties.
- Formulations and Delivery Systems: Improved methods for administering drugs, such as sustained-release formulations, topical applications, or novel excipients that enhance bioavailability.
- Therapeutic Uses: New indications or specific patient populations for existing anti-inflammatory drugs.
- Manufacturing Processes: Efficient and cost-effective methods for synthesizing active pharmaceutical ingredients.
- Combination Therapies: Patents covering the co-administration of multiple drugs to achieve synergistic effects or manage complex inflammatory conditions.
Key Players and Their Patenting Activities in Inflammation
Several major pharmaceutical companies and research institutions hold significant patent portfolios related to anti-inflammatory therapies. While direct competitors to the specific compounds claimed in 6,623,744 would depend on the exact chemical structures and their specific biological targets, the general landscape includes:
- AbbVie Inc.: Known for its blockbuster anti-inflammatory drugs like Humira (adalimumab), AbbVie holds numerous patents on biologics (monoclonal antibodies targeting TNF-alpha), small molecules (JAK inhibitors), and their formulations and uses for conditions like rheumatoid arthritis, psoriasis, and inflammatory bowel disease.
- Johnson & Johnson: Through its Janssen Pharmaceutical Companies, J&J has a strong presence in inflammation with drugs such as Stelara (ustekinumab) for psoriasis and Crohn's disease, and Remicade (infliximab, biosimilar competition exists), also targeting TNF-alpha. Their patent activity includes novel antibodies, small molecules, and combination therapies.
- Pfizer Inc.: Pfizer has a broad portfolio encompassing small molecule inhibitors (e.g., Xeljanz for rheumatoid arthritis, a JAK inhibitor) and other anti-inflammatory agents. They patent new chemical entities, improved formulations, and specific therapeutic applications.
- Merck & Co., Inc.: Merck's research in inflammation has included various targets. Historically, they have had NSAIDs and are involved in developing new targeted therapies.
- Eli Lilly and Company: Lilly has pursued a range of anti-inflammatory targets, including IL-17 inhibitors (e.g., Taltz) and other cytokine-targeting therapies. Their patenting strategy involves new biologics, small molecules, and methods of treatment.
- Gilead Sciences, Inc.: While known for antivirals, Gilead has also made inroads into inflammatory diseases with JAK inhibitors like filgotinib, used for rheumatoid arthritis.
- Bristol Myers Squibb Company: BMS has a strong focus on immunology and inflammation, with drugs like Orencia (abatacept) targeting T-cell activation and ongoing research in new pathways.
Patent Trends in Anti-Inflammatory Research
- Targeted Therapies: A significant trend is the move towards highly specific targeted therapies, such as monoclonal antibodies and small molecule inhibitors that block specific cytokines (e.g., IL-1, IL-6, TNF-alpha, IL-17, IL-23) or intracellular signaling pathways (e.g., JAK-STAT pathway). Patents in this area often claim the specific antibody, its mechanism of action, or its use in particular disease subtypes.
- Biologics and Biosimilars: The rise of biologic drugs has led to extensive patenting of antibody sequences, production methods, and therapeutic uses. Concurrently, there is significant patent activity surrounding biosimilar development, focusing on demonstrating similarity to the reference product and ensuring no infringement of existing patents.
- Oral Small Molecules: The development of oral small molecule inhibitors, particularly JAK inhibitors, has expanded treatment options and is a fertile ground for patent filings covering novel scaffolds, specific isomer forms, and optimized formulations for oral administration.
- Precision Medicine: Patents are increasingly specifying therapeutic uses for particular patient subgroups identified by biomarkers, reflecting the shift towards personalized medicine.
- Drug Repurposing: Existing drugs approved for other indications are being investigated for anti-inflammatory properties, leading to patent filings for new uses.
- Combination Therapies: Patents are often filed for novel combinations of existing or new anti-inflammatory agents, aiming to improve efficacy or overcome resistance.
The patent landscape around anti-inflammatory agents is dynamic. Companies need to conduct thorough freedom-to-operate (FTO) analyses and patentability searches to navigate this space effectively, especially when developing new compounds or seeking to bring existing ones to market. The expiration of patents like 6,623,744 can open avenues for generic competition or the development of next-generation therapies building upon the foundational chemistry.
What are the potential implications of Patent 6,623,744's expiration?
The expiration of U.S. Patent 6,623,744 on February 26, 2021, has several implications for the pharmaceutical industry:
- Generic Competition: The expiration of the patent allows other companies to manufacture and sell generic versions of any drug that was exclusively covered by this patent, provided they do not infringe on other active patents related to formulation, manufacturing processes, or specific therapeutic uses. This typically leads to a significant decrease in drug prices, increasing accessibility for patients.
- Market Entry for Biosimilars/Generics: If specific compounds claimed in 6,623,744 were commercialized as drugs, the expiration facilitates the entry of bioequivalent or generic versions. This can disrupt the market share of the originator drug.
- Opportunity for Research and Development: The expiration of foundational patents can stimulate further research and development. For example, researchers can now use the expired patented compounds as starting points for developing improved analogs, exploring new therapeutic applications, or creating novel drug delivery systems without the constraint of this specific patent.
- Freedom to Operate: Companies planning to develop or market drugs based on similar amino(thio)phosphonic acid structures can now do so with greater freedom, provided they navigate any remaining, still-active patents on related technologies.
- Impact on Investment: For investors, the expiration may signal a shift in market dynamics, potentially impacting the valuation of companies holding original patents for drugs derived from this technology, while creating opportunities in the generic or novel development space.
- No Guaranteed Market Entry: It is crucial to note that patent expiration does not automatically grant market approval. Drugs must still undergo rigorous regulatory review (e.g., by the FDA in the U.S.) for safety and efficacy before they can be marketed. Additionally, other patents covering specific formulations, polymorphs, or methods of use may still be in force, necessitating careful patent landscape analysis.
What is the commercial relevance of amino(thio)phosphonic acid derivatives in the pharmaceutical industry?
Amino(thio)phosphonic acid derivatives represent a class of compounds with significant commercial relevance in the pharmaceutical industry, primarily due to their diverse biological activities. Historically, phosphonates have found applications as:
- Antivirals: Compounds like cidofovir and tenofovir are nucleotide analogs with phosphonate groups, used to treat viral infections such as cytomegalovirus (CMV) and HIV.
- Antibacterials: Certain phosphonate compounds have demonstrated antibacterial properties.
- Anticancer Agents: Research has explored phosphonates for their potential in cancer therapy.
- Bone Metabolism Modulators: Bisphosphonates (a subclass of phosphonates) are widely used to treat osteoporosis and bone metastases due to their ability to inhibit osteoclast activity. Examples include alendronate (Fosamax) and zoledronic acid (Zometa).
- Anti-inflammatory Agents: As indicated by Patent 6,623,744, this class of compounds also exhibits anti-inflammatory potential. The mechanism of action in inflammation can involve modulation of cytokine production, inhibition of specific enzymes involved in inflammatory pathways, or other immunomodulatory effects.
The commercial success of bisphosphonates, in particular, highlights the significant market potential for phosphonate-based drugs. The development of new amino(thio)phosphonic acid derivatives, as described in Patent 6,623,744, aimed to expand this therapeutic utility into areas like inflammation. The commercial relevance is driven by the unmet medical needs in these therapeutic areas and the potential for novel mechanisms of action or improved safety and efficacy profiles compared to existing treatments. However, the ultimate commercial success of any given derivative depends on extensive preclinical and clinical trials, regulatory approval, market demand, and the competitive landscape, including existing patents and therapies.
Key Takeaways
- Patent Expiration: United States Patent 6,623,744 expired on February 26, 2021, removing patent protection for the claimed substituted amino(thio)phosphonic acid derivatives in the U.S.
- Core Innovation: The patent covers novel chemical entities with potential anti-inflammatory properties, defined by specific structural formulae.
- Therapeutic Focus: The primary disclosed use is in treating inflammatory diseases, with specific examples of conditions mentioned in dependent claims.
- Landscape Dynamics: The anti-inflammatory drug market is highly competitive, characterized by extensive patenting of novel molecules, formulations, and therapeutic uses by major pharmaceutical players.
- Post-Expiration Opportunities: Patent expiration enables generic competition, market entry for off-patent drugs, and provides a research foundation for developing next-generation therapies or new applications.
Frequently Asked Questions
-
Can any company now manufacture and sell drugs based on the chemical structures claimed in Patent 6,623,744 in the U.S.?
While the patent itself has expired, other active patents covering specific formulations, manufacturing processes, or distinct therapeutic uses of these compounds might still be in force. Companies must conduct comprehensive freedom-to-operate analyses before commercialization.
-
What is the difference between amino(thio)phosphonic acids and bisphosphonates?
Bisphosphonates are a subclass of phosphonates characterized by two phosphonate groups linked by a carbon atom (P-C-P backbone). Amino(thio)phosphonic acids, as described in Patent 6,623,744, feature an amino group and a phosphonic acid (or thiophosphonic acid) group, with structural variations defining their specific chemical identity and therapeutic potential.
-
Were any specific drugs developed directly from the claims of Patent 6,623,744?
A detailed review of drug approval databases and patent litigation records would be required to confirm if specific marketed drugs directly derive from the claims of this particular patent. Patent expiration does not inherently mean a drug was brought to market.
-
What are the typical mechanisms of action for anti-inflammatory phosphonate derivatives?
Mechanisms vary widely but can include modulating pro-inflammatory cytokine production (e.g., TNF-alpha, interleukins), inhibiting enzymes involved in inflammatory cascades (e.g., cyclooxygenases), or interacting with immune cell signaling pathways.
-
Does the expiration of this patent affect the development of new anti-inflammatory drugs not related to amino(thio)phosphonic acids?
No, the expiration of Patent 6,623,744 only removes patent protection for the specific chemical structures and uses claimed within that patent. It does not impact the patentability or development of entirely different classes of anti-inflammatory agents.
Citations
[1] United States Patent 6,623,744. (2003). Substituted amino(thio)phosphonic acid derivatives and pharmaceutical preparations containing them. Issued August 26, 2003.
More… ↓
⤷ Start Trial
|
